|
The Asia Pharma Expo 2025, which will be held between February 12 and14 2025 at the Bangabandhu Bangladesh-China Friendship Exhibition Center (BCFEC), Dhaka Bangladesh, is all poised to highlight the remarkable collaborative potential of the Bangladesh pharmaceutical market with the Indian pharmaceutical market.
The Asia Pharma Expo 2025 marks 23 years of bridging pharmaceutical innovation in Bangladesh. With over 800 exhibitors from 32 countries and an expected turnout of more than 14,500 trade visitors, the event serves as a hub for showcasing the latest technologies and forging global connections.
According to industry experts, there is a pressing need for strategic collaboration between the Bangladesh and Indian pharmaceutical industry. Organized by GPE Expo Pvt. Ltd. in partnership with the Bangladesh Association of Pharmaceutical Industries, this premier event will continue to showcase the immense opportunities for growth in the region.
One of the key highlights of the event is The India Pavilion, organized by the Pharmaceuticals Export Promotion Council of India (Pharmexcil).
Pharmexcil Director General K. Raja Bhanu remarked on the growing synergies between the two nations in the pharmaceutical sector. “The Bangladesh pharmaceutical industry has emerged as a powerhouse in South Asia, meeting 98% of its domestic medicine demand while exporting to over 142 countries globally. With a market size of over USD 6 billion in 2024, the sector offers unprecedented opportunities for collaboration,” said Bhanu.
He emphasized the importance of cross-border partnerships, particularly in Active Pharmaceutical Ingredients (APIs), where India’s expertise in API manufacturing could complement Bangladesh’s robust pharmaceutical formulation capacity.
“The establishment of the API Manufacturing Park near Dhaka is a game-changer for the region. Indian API and bulk active manufacturers have a golden opportunity to explore joint ventures, technology tie-ups, and raw material exports to foster mutual growth,” Bhanu added.
The Bangladesh pharmaceutical industry has seen exponential growth in recent years. With a market value of approximately USD 3 billion in 2023, the industry is on track to more than double in the near future. Its success lies in the strength of nearly 300 domestic manufacturers that dominate over 90% of the local market share, producing medicines that cater to both local and international demands.
Exports, which currently exceed USD 400 million, are expected to grow even further as the country strengthens its presence in regulated markets. Notably, Bangladesh is leveraging its API Manufacturing Park to scale up production and reduce dependency on imports, creating a fertile ground for partnerships with global players like India.
The collaboration between Bangladesh and India holds immense potential to transform the pharmaceutical landscape of South Asia. With Indian expertise in API manufacturing and technology and Bangladesh’s growing formulation capabilities, the synergy could lead to increased competitiveness in the global market.
As Raja Bhanu aptly summarized, “The time is now to build bridges between the Indian and Bangladesh pharmaceutical industries. Together, we can not only cater to regional demands but also position South Asia as a global leader in pharmaceutical innovation and supply. The Asia Pharma Expo 2025 has undoubtedly set the stage for such strategic alliances, paving the way for a brighter, collaborative future in the pharmaceutical sector.”
The exhibition underscores the comprehensive ecosystem required for advancing pharmaceutical manufacturing, ranging from biotech and healthcare to nutraceuticals and cosmetics. The India Pavilion, featuring state-of-the-art products and solutions from Indian manufacturers, has been a major highlight, reinforcing India’s leadership in pharma innovation.
|